News headlines about Meridian Bioscience (NASDAQ:VIVO) have been trending somewhat positive recently, Accern reports. The research firm rates the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Meridian Bioscience earned a coverage optimism score of 0.14 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.6611818023147 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the news stories that may have impacted Accern’s rankings:

Several analysts have commented on the stock. Zacks Investment Research downgraded shares of Meridian Bioscience from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. BidaskClub downgraded shares of Meridian Bioscience from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Three equities research analysts have rated the stock with a sell rating and four have assigned a hold rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $14.75.

Shares of Meridian Bioscience (NASDAQ:VIVO) traded up 0.70% during mid-day trading on Friday, reaching $14.30. 117,127 shares of the company’s stock traded hands. Meridian Bioscience has a 12 month low of $10.75 and a 12 month high of $19.85. The company has a 50 day moving average of $13.83 and a 200 day moving average of $14.20. The company has a market cap of $603.50 million, a price-to-earnings ratio of 28.60 and a beta of 0.86.

Meridian Bioscience (NASDAQ:VIVO) last issued its quarterly earnings results on Thursday, July 27th. The company reported $0.16 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.16. Meridian Bioscience had a return on equity of 16.93% and a net margin of 10.77%. The firm had revenue of $50.14 million for the quarter, compared to analyst estimates of $49.13 million. During the same period in the previous year, the firm earned $0.21 earnings per share. The company’s revenue was down 1.0% compared to the same quarter last year. Analysts expect that Meridian Bioscience will post $0.67 earnings per share for the current fiscal year.

In other Meridian Bioscience news, Chairman John A. Kraeutler purchased 7,000 shares of the company’s stock in a transaction on Thursday, August 24th. The shares were purchased at an average cost of $13.67 per share, with a total value of $95,690.00. Following the completion of the purchase, the chairman now owns 345,230 shares in the company, valued at $4,719,294.10. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 2.30% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Meridian Bioscience (VIVO) Stock Price” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at

About Meridian Bioscience

Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.

Insider Buying and Selling by Quarter for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Stock Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related stocks with our FREE daily email newsletter.